Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8786180 | Clinical Oncology | 2018 | 12 Pages |
Abstract
WWCXB is likely to be cost-effective compared with both WWEBRT alone and radical surgery. These findings support the use of CXB boost as an adjunct to a watch and wait strategy.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
C. Rao, F.M. Smith, A.P. Martin, A.S. Dhadda, A. Stewart, S. Gollins, B. Collins, T. Athanasiou, A. Sun Myint,